Aurinia appoints Chair Kevin Tang as CEO; entire C-suite replaced effective March 23, 2026

Aurinia Pharmaceuticals Inc.

Kevin Tang (Chair) appointed CEO, succeeding Peter Greenleaf; Greenleaf to consult for 3 months at $600/hr.
Ryan Cole appointed COO ($300k salary, 50% bonus, 150k options); Michael Hearne appointed CFO (same terms).
Departures: Peter Greenleaf, Matthew Donley (COO), Gregory Keenan (CMO), Joseph Miller (CFO) effective March 20-21.
Thomas Wei appointed Chief Scientific Officer; Craig Johnson elected Lead Independent Director.
Kevin Tang will receive no salary, bonuses, or equity for his CEO role.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.